(Q45880512)

17 December 2017

title

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas (English)

1 reference

17 December 2017

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

10

Erlichman C

1 reference

17 December 2017

Pamela J Atherton

8

object named as

Atherton P

1 reference

17 December 2017

author name string

Galanis E

1

1 reference

17 December 2017

Okuno SH

2

1 reference

17 December 2017

Nascimento AG

3

1 reference

17 December 2017

Lewis BD

4

1 reference

17 December 2017

Lee RA

5

1 reference

17 December 2017

Oliveira AM

6

1 reference

17 December 2017

Sloan JA

7

1 reference

17 December 2017

Edmonson JH

9

1 reference

17 December 2017

Randlev B

11

1 reference

17 December 2017

Wang Q

12

1 reference

17 December 2017

Freeman S

13

1 reference

17 December 2017

Rubin J

14

1 reference

17 December 2017

publication date

1 March 2005

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

12

1 reference

17 December 2017

issue

5

1 reference

17 December 2017

page(s)

437-445

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302436

exact match

0 references

cites work

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

7 January 2021

Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

7 January 2021

Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

7 January 2021

Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

7 January 2021

Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

7 January 2021

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302436

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302436

1 reference

17 December 2017

Dimensions Publication ID

0 references

1 reference

17 December 2017